Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 7, 2004 Charly Travers	Pfizer Wants to Be Your Pfriend It seems that the pharmaceutical is limiting its profits in certain markets on its own terms in the hopes that concessions will be sufficient to keep from being handcuffed by Congress.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
The Motley Fool March 19, 2004 Bill Mann	The Drug Reimportation Disaster State-imposed pricing is not natural law. Expect Canada to have a problem supplying all those drugs.
The Motley Fool January 7, 2005 Brian Gorman	Canadian Drug Sales Might End Drug makers may not have to worry about cheap pills flooding into the U.S. from across the border, at least for now, offering a small consolation to investors.
The Motley Fool May 7, 2004 Brian Gorman	CVS Fuels the Drug Debate Thomas Ryan, the CEO of CVS, supports reimporting drugs from Canada before Congress. Drugs from European companies may actually have a greater impact on price.
InternetNews October 13, 2004 Roy Mark	Report: The Internet and Drugs Don't Mix It seems an increasing number of Americans are researching drugs online, but safety fears chill buying.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
The Motley Fool April 12, 2010 Brian Orelli	Pay for Our Drugs or Else Is the pharmaceutical industry's muscle strong enough? In the U.S., health-care reform will increase coverage, but the reform's ability to keep prices in check is fairly limited.
Reason May 2007 Jacob Sullum	Exporting Drug Prices Pharmaceutical companies argue that the higher prices paid by Americans underwrite the research and development that makes new drugs possible, in effect subsidizing consumers in other countries. Reimportation could force our northern neighbors to share that burden.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool December 17, 2009 Kris Eddy	Meds Without Passports The Senate defeats one amendment to allow Americans to import cheaper prescription medicines.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool March 15, 2004 W.D. Crotty	60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks?
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool August 6, 2007 Brian Orelli	Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool December 11, 2006 Michael P. Cecil	Why Doesn't Buffett Buy Drug Companies? Investors, how do you estimate the amount of money that a drug company, or perhaps more simply one of its drugs, will produce over its lifetime?
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
InternetNews June 13, 2005 Roy Mark	Fake Canadian Drug Sites Proliferating New study shows 80 percent of sites claiming to be Canadian drug stores are registered in other countries.
Chemistry World November 2, 2011 Rebecca Trager	Escalating Drug Dearth Spooks White House Manufacturing problems are the principal reason for the rapid growth in drug shortages.
Managed Care October 2005	Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
Managed Care February 2006	For Drugs, the VA Pays Far Less Than Medicare A recent survey indicates that prices for the top 20 drugs used by Medicare enrollees are much higher than prices negotiated by the Department of Veterans Affairs.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.